Rawlins: Seek More Joint Scientific Advice for your PIMs
This article was originally published in Scrip
Executive Summary
Not enough companies that have won coveted PIM designations for their novel drugs are making use of joint scientific advice meetings with UK regulators, the MHRA and NICE, and are instead focusing on guidance from the European Medicine Agency – a situation that needs to change, says MHRA Chairman Sir Michael Rawlins. He added that the two bodies are also working together to bridge the gap that has opened up for products between the scheme and their NICE evaluation.